Silexion Therapeutics Corp (SLXN) saw an uptrend of 47.26% in the recent trading with $0.33 being its most recent. The current price level -97.54% lower than the highest price of $13.56 marked by the stock while trading over the past 52-weeks, whereas it is 60.92% higher than the lowest price of $0.21 the company dropped to over past 52-weeks. The latest news story on SLXN appeared in (GlobeNewswire) under the title “Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference”.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Sponsored
Squeezing the time span to 30 day period shows us the stock is currently trading -28.49% below one month high and is +60.92% above of the lowest during that time. Looking into the simple moving average, Silexion Therapeutics Corp (SLXN)’s stock stands at a SMA-50 of $0.4442 while that of 5-day is reading $0.2438.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
Silexion Therapeutics Corp Earnings – What Happened With SLXN
Coming around sales and income figures on SLXN Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
SLXN – Silexion Therapeutics Corp Stock Earnings Estimates
1 analysts covering the stock at Wall Street were agreed upon that EPS consensus.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 3.87 million. SLXN does have institutional investors; and they hold 29.48% of the stock.
Silexion Therapeutics Corp – Insider Activity and Holdings
Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Silexion Therapeutics Corp has a debt to equity ratio of 1.32.
